The market turmoil caused by rising rates and continued uncertainty has soured growth prospects in nearly every sector of the economy, including life sciences, biotech and lab real estate. After record-setting raises, cresting at $43.3B in 2021, the biotech industry started 2022 with growth curtailed, shifting expectations and venture capitalists and fund managers altering investment strategies.  “Life science, by its nature, is a volatile industry, and we’re starting to see a little bit of that re-emerging,” Colliers Director of Research Aaron Jodka said. “It’s kind of like interest rates. We’re coming off all-time lows, but they’re still very attractive compared to history. That context matters. If you’re going 150 mph and take your…